Neurocrine Biosciences, Inc.

Good day and welcome to Nuroquin Biosciences year-end and fourth quarter results call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star 1 on your telephone keypad. You may remove yourself by pressing star 2. Please note today's call will be recorded and I'll be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations. Please go ahead.

Thank you, and a good Wednesday morning to everyone. Welcome to Neurocrine Biosciences' fourth quarter and full year 2023 earnings call. Joining us today are Kevin Gorman, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Irie Roberts, Chief Medical Officer, Eric Benevich, Chief Commercial Officer, and Kyle Gaino, Chief Business Development and Strategy Officer. During the call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filing. Today's prepared remarks will be a bit longer in duration versus prior earnings calls, as we do have a lot of ground to cover. I can assure you that we will do our best to address all of your questions when we get into Q&A. So now, I'll turn the call over to Kevin. Thank you, Todd, and good morning, everyone.

So we had a great 2023. I said the same thing about 2022, and it was great. I said there are very few years you get like 2022, and we then had one of those years in 2023. Both of those years were not without their ups and downs, but on the whole, the business performed exceptionally well. I mean, looking at 2023, again, incredible continued growth for Ingresa in its sixth year on the market. Expansion of Ingresa intellectual property out to 2038. Approval of Ingresa in another indication in Huntington's disease. We also had Kronesser Front phase three data that beat even our high expectations for that. And a clinical pipeline that grew more in that one year than we've ever experienced at NERC and in the past, and then a preclinical pipeline that is growing quite a bit. Now, we expect an equally successful 2024, and I'm not going to go into the details of that because my colleagues in the room are going to talk about that. But right now, let's take a snapshot of 2023 from a financial perspective. from Matt, and he will also give you how we're viewing 2024. Matt? Thanks, Kevin.